Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among ...

Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ...

A larger diameter of the main pulmonary artery predicts poorer outcomes in pulmonary arterial hypertension (PAH) patients, a ...

Boosting MTMR7 production reversed signs of pulmonary arterial hypertension in a mouse model of PAH and may serve as a ...

You have full access to this article via your institution. Pulmonary arterial hypertension (PAH) is a chronic progressive disease characterized by endothelial cell (EC) dysfunction, substantial ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

There is no cure yet, but there are things that can and using oxygen. PH is different for everybody, so talk to your doctor to find the best treatment for you.

Data show people with pulmonary arterial hypertension tend to stay in the hospital longer and have higher medical bills.

Data from this study showed that treatment with Winrevair, when added to background PAH therapy, achieved a statistically significant and clinically meaningful reduction in the risk of morbidity ...

Corsair Pharma Announces Successful Completion of Preclinical Program for Its Treprostinil Prodrug Transdermal System ...

That increase in survival is seen as a major advance in PAH treatment, which has a five-year survival rate of a little over 40%, and is backed up by functional improvements, including a ...

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.